Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Investing Activities data on file, last reported at -$49.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$49.0 million, down 140.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.0 million (up 785.66% YoY), and the FY2025 annual result was $236.0 million, up 1411.11% from the prior year.
• Cash from Investing Activities advanced to -$49.0 million in Q1 2026 per RARE's latest filing, from -$72.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $120.0 million in Q1 2025 and troughed at -$275.5 million in Q3 2024.
• A 5-year average of $2.7 million and a median of $64.3 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 397.91% in 2023, then sank 528.5% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$171.6 million in 2022, then jumped by 37.64% to -$107.0 million in 2023, then jumped by 195.78% to $102.5 million in 2024, then slumped by 170.48% to -$72.2 million in 2025, then soared by 32.18% to -$49.0 million in 2026.
• Business Quant data shows RARE's Cash from Investing Activities at -$49.0 million in Q1 2026, -$72.2 million in Q4 2025, and $117.2 million in Q3 2025.